Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting Dec 4, 2018
Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate Dec 3, 2018
Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference Nov 19, 2018
Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference Nov 5, 2018
Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data Nov 1, 2018
Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax Oct 30, 2018
Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update Oct 26, 2018
Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference Oct 24, 2018
Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update Oct 22, 2018
Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers Oct 1, 2018
